Non-small cell lung cancer
Not recruitingStudy of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations
Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations
- Disease:Non-small cell lung cancer
- Substances:PembrolizumabDatopotamab Deruxtecan
Belgium- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
